Get the Stockscreener App
14.43
0.38%
0.0596
Takeda Pharmaceutical Co Adr stock is traded at $14.43, with a volume of 1.35M.
It is up +0.38% in the last 24 hours and up +2.96% over the past month.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
See More
Previous Close:
$14.37
Open:
$14.37
24h Volume:
1.35M
Relative Volume:
0.50
Market Cap:
$45.59B
Revenue:
$29.63B
Net Income/Loss:
$260.53M
P/E Ratio:
183.12
EPS:
0.0788
Net Cash Flow:
$5.51B
1W Performance:
+1.02%
1M Performance:
+2.96%
6M Performance:
-4.91%
1Y Performance:
+6.38%
1-Day Range:
$14.37
$14.53
1-Week Range:
$14.16
$14.53
52-Week Range:
$12.80
$15.69
Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile
Compare TAK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TAK
Takeda Pharmaceutical Co Adr
|
14.43 | 45.40B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
ZTS
Zoetis Inc
|
117.73 | 52.03B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
9.5801 | 42.13B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.91 | 34.19B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
486.74 | 20.88B | 3.08B | 1.24B | 1.07B | 25.61 |
Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-16-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-19-22 | Upgrade | Cowen | Market Perform → Outperform |
| Oct-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-19-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-19 | Initiated | Cowen | Market Perform |
| Aug-15-19 | Downgrade | Daiwa Securities | Outperform → Neutral |
View All
Takeda Pharmaceutical Co Adr Stock (TAK) Latest News
Celiac Disease Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
Peptide Therapeutics Market Size to Reach USD 82.19 Billion by 2032; Surging Requirements for Targeted Medicines in Oncology Augment Market Expansion - GlobeNewswire Inc.
Denali Enters Into a $275M Funding Deal With Royalty Pharma - Finviz
INNOVENT BIO Completes Introduction of Takeda, Raising ~HKD780M Net - AASTOCKS.com
Eli Lilly Upgraded, Chewy Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Coca-Cola Upgraded, Boeing Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
ADR movements on the 11th: In yen terms, Kirin HD, Takeda Pharmaceutical, and Mitsui Metals showed gains. - 富途牛牛
Takeda Pharma ADR earnings beat by $278.84, revenue fell short of estimates - Investing.com Nigeria
CMBI Adds INNOVENT BIO (01801.HK) TP to $110.62 on Strategic Partnership with Takeda Pharmaceutical - AASTOCKS.com
BofAS Elevates INNOVENT BIO (01801.HK) TP to $113 as Co-op with Takeda Pharmaceutical Marks Major Step Towards Becoming Multinational Pharma Firm - AASTOCKS.com
CLSA Lifts INNOVENT BIO's TP to HKD120.1; Takeda Pharma Co-op Positive for Product Development - AASTOCKS.com
Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors - Placera.se
INNOVENT BIO Opens Up 10% on Shr Issuance to Takeda Pharma at ~30% Premium w/ Licensing Deal Worth USD11.4B - AASTOCKS.com
INNOVENT BIO Issues Shrs at ~30% Premium to Takeda Pharma w/ Licensing Deal Involving USD11.4B - AASTOCKS.com
Bank of America Upgraded, Allstate Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
TAK vs. DSNKY: Which Stock Is the Better Value Option? - MSN
Walt Disney Upgraded, Southwest Airlines Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Takeda Pharmaceutical Company Limited (TAK) Stock Price, News, Quote & History - Yahoo
Pharma stocks in Asia fall as Trump announces 100% tariffs - Investing.com
5 Best High-Yield Dividend Stocks to Buy Now - The Motley Fool
Takeda’s narcolepsy drug shows positive results in phase 3 trials - Investing.com
U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease - Placera.se
Japan's Takeda weighs India for global trials to speed up drug launches - MSN
Takeda Pharmaceutical ADR Earns RS Rating Upgrade - MSN
IBD Rating Upgrades: Warrior Met Coal Shows Improved Technical Strength - inkl
IBD Rating Upgrades: Takeda Pharmaceutical ADR Shows Improved Technical Strength - MSN
IBD Rating Upgrades: Genmab ADR Shows Improved Relative Price Strength - inkl
Waltham biotech’s latest pharma deal valued at $2B - The Business Journals
TAK’s Market Quandary: Decoding the Ups and Downs of 2025 - investchronicle.com
Blair William & Co. IL Cuts Stock Position in Takeda Pharmaceutical Co. (NYSE:TAK) - Defense World
Takeda Pharmaceutical Co Adr Stock (TAK) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.22%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):